Medivation, Orexigen Highlight Late-Stage Strategies for Closely-Watched Drugs
This article was originally published in The Pink Sheet Daily
Medivation will push on with Phase III trials despite an Alzheimer's failure, while Orexigen says a competitor's obesity drug could affect partnering plans.
You may also be interested in...
Pfizer/Medivation End Dimebon Development Following Another Failed Alzheimer’s Trial
A second failed efficacy trial, CONCERT, provided the final nail in the coffin for the once-promising treatment for Alzheimer’s disease, serving as a cautionary tale against excessive enthusiasm for early clinical trial results.
Orexigen Insists Revised Contrave Data Should Not Affect Timing Of NDA
FDA tells the biotech corrections to secondary endpoint data for one pivotal study for its diet pill filing comprise only a clinical amendment.
Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
The drug's inability to show an efficacy benefit highlights risks of Alzheimer's disease drug development and pressures Pfizer to pull off some pipeline wins.